LLY - Eli Lilly and Company Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

LLY

ELI LILLY AND COMPANY

NYSE

$1137.75

▲ UP 1.98% (22.05)

KEY STATISTICS

Market Cap$1.05 T

52w High$1292.65

52w Low$712.05

Dividend Yield0.59%

FrequencyQuarterly

P/E36.13

Volume2.11M

Shares Out.941.74M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

David A. Ricks

COMPENSATION 2026

Salary$1,700,000

Stock Awards$23,325,000

Incentive Plan Pay$6,485,500

All Other Comp.$736,201

Total$36,698,337

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 1, 1972

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

50,000

PRICE TARGET

Target High$1500.00

Target Low$940.00

Target Median$1370.00

Target Consensus$1324.67

UPCOMING EARNINGS

DateOct 29, 2026

DayThursday

Rev. Est.$22.16B

OCT

THU

SPLIT RECORD

DATE	TYPE	RATIO
1997-10-16	Forward	2:1
1995-12-21	Forward	2:1
1989-05-01	Forward	2:1
1986-01-30	Forward	2:1

PRICE

$1137.75 ▲ UP 1.98% (+$22.05)

OVERLAYS

About Eli Lilly and Company

https://www.lilly.com ↗

Eli Lilly and Company, founded in 1876 and based in Indianapolis, develops and markets global pharmaceuticals including insulin, cancer treatments, and therapies for diabetes, rheumatoid arthritis, depression, and COVID-19, through numerous collab...

INDUSTRY

Drug Manufacturers - General

A PRODUCT ELI LILLY AND COMPANY IS KNOWN FOR

Zepbound

Zepbound, an FDA-approved injectable prescription for chronic weight management in adults with obesity or overweight with related conditions, contains tirzepatide, a dual GIP and GLP-1 receptor agonist, and is a key growth driver for Eli Lilly in ...